Having trouble accessing articles? Reset your cache.

IMO-2055: Phase Ib started

Idera said Merck began a dose-escalation Phase Ib trial to evaluate IMO-2055 in combination with cisplatin, fluorouracil

Read the full 170 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE